{"product_id":"roche-bcg-matrix","title":"Roche  Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRoche’s BCG Matrix snapshot shows how its key business units and product lines map across growth and market share—revealing potential Stars in oncology, Cash Cows in diagnostics, and areas at risk. This concise preview highlights strategic priorities and resource implications, but the full BCG Matrix delivers quadrant-level placements, actionable recommendations, and financial context. Purchase the complete report for a Word analysis and Excel summary that guide capital allocation, portfolio pruning, and growth bets with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVabysmo (Faricimab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVabysmo (faricimab) is Roche’s high-growth ophthalmology star, with 2025 sales of CHF 4.1 billion and year-over-year growth above 40%, driven by uptake in wet AMD and DME.\u003c\/p\u003e\n\u003cp\u003eIts flexible dosing (up to every 16 weeks) helped capture market share from Bayer\/Regeneron’s Eylea, lowering treatment burden and boosting payer adoption in the US and EU.\u003c\/p\u003e\n\u003cp\u003eRoche is investing in global rollout, real-world evidence programs and head-to-head studies; capex and H2 2025 field spend rose ~25% to secure long-term market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhesgo (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhesgo (breast cancer) is a Roche HER2 franchise star: a fixed-dose subcutaneous combo of pertuzumab and trastuzumab whose sales jumped \u0026gt;50% in 2025, reaching an estimated $1.2bn–$1.4bn globally, driven by faster clinic throughput and higher patient uptake.\u003c\/p\u003e\n\u003cp\u003eIts convenience is rapidly taking share and blunting biosimilar threat, but Roche must fund geographic rollouts and convert IV patients; sustained investment will let Phesgo transition into a cash cow as market penetration exceeds 40% in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcrevus (Multiple Sclerosis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcrevus remains Roche’s top-selling drug, posting CHF 7.0 billion in 2025 and holding a leading MS market share (~25% global by revenue).\u003c\/p\u003e\n\u003cp\u003eThe 2024 subcutaneous Zunovo launch broadened uptake—12% of 2025 Ocrevus prescriptions in Europe—and refreshed the brand, extending its lifecycle. \u003c\/p\u003e\n\u003cp\u003eDespite product maturity, robust demand for novel MS therapies keeps Ocrevus in the BCG Stars quadrant: high market share and continued market growth ahead of patent expiries. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemlibra (Hemophilia A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHemlibra (emicizumab) transformed hemophilia A care, delivering double-digit growth to CHF 4.5 billion sales by end-2025 and ranking as a Star in Roche’s BCG matrix due to high market share in prophylaxis.\u003c\/p\u003e\n\u003cp\u003eRoche holds dominant prophylaxis share, expanding into pediatric and inhibitor patients globally while investing in next-gen follow-ons to defend vs gene therapies and new competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 4.5 billion sales (2025)\u003c\/li\u003e\n\u003cli\u003eDouble-digit CAGR since 2022\u003c\/li\u003e\n\u003cli\u003eLeading global prophylaxis market share\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D on next-gen follow-ons vs gene therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing (NGS) Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche Diagnostics is shifting to advanced sequencing with SBX, which Roche announced in November 2025 can decode a human genome in under four hours, targeting a personalized medicine market growing at ~14% CAGR to $45B by 2027.\u003c\/p\u003e\n\u003cp\u003eThe unit is first-to-market in clinical genomics, receiving \u0026gt;€1.2bn capex since 2024 to integrate diagnostics with Roche Pharma to drive companion diagnostics and targeted therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSBX: \u0026lt;4-hour genome (Nov 2025)\u003c\/li\u003e\n\u003cli\u003eMarket: ~14% CAGR, ~$45B by 2027\u003c\/li\u003e\n\u003cli\u003eInvestment: \u0026gt;€1.2bn capex since 2024\u003c\/li\u003e\n\u003cli\u003eStrategic goal: tie diagnostics to pharma for higher-margin care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche blockbuster surge: Vabysmo, Ocrevus, Hemlibra, Phesgo drive strong 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche Stars: Vabysmo CHF4.1bn (2025, +40% YoY); Phesgo $1.3bn (2025, +50%); Ocrevus CHF7.0bn (2025, ~25% MS share); Hemlibra CHF4.5bn (2025, double-digit CAGR); Diagnostics SBX \u0026lt;4h genome (Nov 2025), \u0026gt;€1.2bn capex since 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\u003c\/th\u003e\n\u003cth\u003eGrowth\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVabysmo\u003c\/td\u003e\n\u003ctd\u003eCHF4.1bn\u003c\/td\u003e\n\u003ctd\u003e+40% YoY; q16w dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhesgo\u003c\/td\u003e\n\u003ctd\u003e$1.3bn\u003c\/td\u003e\n\u003ctd\u003e+50%; subQ HER2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003eCHF7.0bn\u003c\/td\u003e\n\u003ctd\u003e~25% MS rev share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemlibra\u003c\/td\u003e\n\u003ctd\u003eCHF4.5bn\u003c\/td\u003e\n\u003ctd\u003edouble‑digit CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Roche’s portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Roche BCG Matrix mapping units into quadrants for fast strategic decisions and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics Division Core Lab Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche’s Diagnostics division, led by centralized lab and pathology platforms, generated about CHF 13.8 billion in 2025, acting as a major cash cow for the group.\u003c\/p\u003e\n\u003cp\u003eThese mature, high-margin platforms hold dominant global shares in core lab and pathology, delivering predictable recurring revenue from consumables and service contracts.\u003c\/p\u003e\n\u003cp\u003eLow growth but strong margins let Roche fund R\u0026amp;D (CHF 13.7 billion group R\u0026amp;D spend in 2024) and sustain dividends while driving efficiency gains to maximize free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlecensa (Lung Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlecensa (alectinib) is Roche’s cash cow in ALK+ non‑small cell lung cancer, delivering stable sales around CHF 3.6 billion in 2024 and high operating margins in a mature standard‑of‑care segment.\u003c\/p\u003e\n\u003cp\u003eMarket adoption is entrenched—first‑line global share \u0026gt;60%—so promotional spend is low versus new launches, keeping net cash flow steady.\u003c\/p\u003e\n\u003cp\u003eRoche redirects Alecensa profits to fund its oncology pipeline; Roche invested CHF 11.2 billion in R\u0026amp;D in 2024, much of which supports early‑stage cancer programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXolair (Immunology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXolair (immunology) remains a Roche cash cow, holding top market share in chronic hives and asthma and driving CHF 2.8 billion in sales in 2025 after new food-allergy approvals. The underlying markets are mature, so marginal marketing and R\u0026amp;D costs are low while pricing stays stable. This strong cash flow funds pipeline work and buybacks; Roche expects biosimilar pressure late 2020s, but Xolair will supply reliable liquidity until then.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes Care (Accu-Chek)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Accu-Chek franchise is a cornerstone of Roche’s diabetes care, delivering stable cash flow from ~30 million users worldwide and a \u0026gt;40% market share in strip-based SMBG (self-monitoring blood glucose) in 2024, in a mature market with low volume growth.\u003c\/p\u003e\n\u003cp\u003ePricing pressure and single-digit CAGR weigh on revenue, but optimized plants and \u0026gt;25% gross margins keep it a high-margin cash cow funding R\u0026amp;D into digital health and continuous glucose monitoring (CGM).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30M users global\u003c\/li\u003e\n\u003cli\u003e40% strip SMBG market share (2024)\u003c\/li\u003e\n\u003cli\u003eSingle-digit CAGR; pricing pressure\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;25%\u003c\/li\u003e\n\u003cli\u003eFunds CGM\/digital health R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerjeta (Oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePerjeta (oncology) remains a high-volume HER2+ breast cancer drug, generating about CHF 2.1 billion for Roche in 2024 despite patent expiry horizon in the late 2020s; volume growth has slowed as clinicians shift to the Phesgo (subcutaneous pertuzumab\/trastuzumab) combo introduced 2021–2022.\u003c\/p\u003e\n\u003cp\u003eEstablished inclusion in adjuvant and metastatic protocols keeps Perjeta a steady cash source; Roche reported gross margins above 70% on the product in 2024 while prioritizing cost discipline and simplified supply to sustain returns before biosimilar entry intensifies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~CHF 2.1bn\u003c\/li\u003e\n\u003cli\u003eGrowth slowing; Phesgo substitution since 2022\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;70% (2024)\u003c\/li\u003e\n\u003cli\u003ePatent cliff late 2020s; biosimilar risk ahead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche’s high‑margin cash cows fund CHF13.7bn R\u0026amp;D \u0026amp; dividends amid biosimilar risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s cash cows: Diagnostics platforms CHF 13.8bn (2025); Alecensa CHF 3.6bn (2024); Xolair CHF 2.8bn (2025); Accu‑Chek ~30M users, \u0026gt;40% SMBG share (2024); Perjeta CHF 2.1bn (2024). These mature, high‑margin businesses fund CHF 13.7bn group R\u0026amp;D (2024) and dividends while offsetting late‑2020s biosimilar risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eCHF 13.8bn (2025)\u003c\/td\u003e\n\u003ctd\u003eRecurring consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlecensa\u003c\/td\u003e\n\u003ctd\u003eCHF 3.6bn (2024)\u003c\/td\u003e\n\u003ctd\u003e1st‑line share \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXolair\u003c\/td\u003e\n\u003ctd\u003eCHF 2.8bn (2025)\u003c\/td\u003e\n\u003ctd\u003eTop immunology share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccu‑Chek\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~30M users; \u0026gt;40% SMBG (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerjeta\u003c\/td\u003e\n\u003ctd\u003eCHF 2.1bn (2024)\u003c\/td\u003e\n\u003ctd\u003eGross margin \u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eRoche  BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Roche BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. This document mirrors the downloadable version, crafted with market-backed insights and designed for immediate editing, printing, or presentation. Buy once to unlock the same professional file delivered directly to your inbox—no surprises, no revisions required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747750195577,"sku":"roche-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/roche-bcg-matrix.png?v=1772201561","url":"https:\/\/growthsharematrix.com\/products\/roche-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}